Renaissance Technologies’s Ortho Clinical Diagnostics Holdings plc Ordinary Shares OCDX Stock Holding History

Renaissance Technologies’s Portfolio OCDX Stock Details OCDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-306,600	Closed	-$5.72M	–	4698
2022 Q1	$5.72M	Buy	306,600 +205,700	+204%	+$3.7M	0.01%	1492
2021 Q4	$2.16M	Buy	100,900 +62,600	+163%	+$1.23M	﹤0.01%	2080
2021 Q3	$708K	Sell	38,300 -186,000	-83%	-$3.75M	﹤0.01%	2731
2021 Q2	$4.8M	Buy	+224,300	New	+$4.56M	0.01%	1660

Other funds holding OCDX

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Renaissance Technologies's OCDX Position: Q2 2022 in Review

Renaissance Technologies sold out of Ortho Clinical Diagnostics Holdings plc Ordinary Shares (OCDX) in Q2 2022, closing a stake of 306,600 shares — an estimated $5.72M sold.

Renaissance Technologies first reported a position in OCDX in Q2 2021 and held it in 4 quarters. The position peaked at $5.72M in Q1 2022. 1 fund tracked by Wall St. Rank holds OCDX as of Q2 2022.

Renaissance Technologies reported no remaining Ortho Clinical Diagnostics Holdings plc Ordinary Shares position as of Q2 2022 after selling out during the quarter.
Renaissance Technologies sold 306,600 Ortho Clinical Diagnostics Holdings plc Ordinary Shares shares in Q2 2022, an estimated $5.72M.
Renaissance Technologies first reported a position in Ortho Clinical Diagnostics Holdings plc Ordinary Shares in Q2 2021 and held it in 4 quarters.
Renaissance Technologies's Ortho Clinical Diagnostics Holdings plc Ordinary Shares position peaked at $5.72M in Q1 2022.
1 fund tracked by Wall St. Rank held Ortho Clinical Diagnostics Holdings plc Ordinary Shares as of Q2 2022.

Based on Renaissance Technologies's 13F filing for Q2 2022, filed 12 Aug 2022.